A clinical investigation on the prevalence of anti-GAD antibody and other autoantibodies in patients with NIDDM
Mitani, Hiroaki Mitani Clinic
To invetigate the prevalence of autoantibodies, such as ANA, RF, ATA, AMA and Anti-GAD antibody, and clinial characteristics on patients's age at the time testing, the duration of diabetes mellitus and treatments, out of 209 NIDDM patients were examined.
The prevalence of autoantibodies in NIDDM patients were 33.5% for ANA, 12.0% for RF, 11.0% for ATA, 15.7% for AMA and 3.8% for anti-GAD antibody respectively. The duration of diabetes mellitus in 8 anti-GAD antibody positive patients were sinificantly shorter than 201 negative patients, and the former were lower than the later in Hba1c leveles. Further anti-GAD positives were slightly tended to increase for AMA to compare with negatives. To have been examined the incidence of autoantibodies in relation to the age in NIDDM, the rates of ANA and AMA progressively increased with age, and that of RF based on the duration gradually did less than 20 years. On the incidence of RF by treatments, Su group (n=98) was significantly higher than Diet group (n=83), and there were not markedly estimated clinical characteristics and that of antibodies in NIDDM with chronic hepatitis C (n=7).
In this study, it may be indicated that the prevalence of autoantibodies and clinical courses in NIDDM are probably related to some immunological mechanisms, glycation, aging and medication, e.g. glibenclamide.
Shikoku Acta Medica
sam_54_4_275.PDF 6 MB